SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
------------------------
FORM 8-K
CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE
SECURITIES EXCHANGE ACT OF 1934
April 14, 1997
------------------------------
Date of Report
AMERICAN PHARMACEUTICAL COMPANY
-----------------------------------------
(Exact name of Registrant as Specified in Charter)
DELAWARE 33-35153-D 84-1138558
- ------------------------------------------------------------------------------
(State or Other Jurisdiction (Commission (IRS Employer
of Incorporation) File Number) Identification No.)
200 WEBRO ROAD PARSIPPANY, NEW JERSEY 07054
- ------------------------------------------------------------------------------
(Address of Principal Executive Offices) (Zip Code)
(201)-515-1000
- ------------------------------------------------------------------------------
(Registrant's telephone number, including area code)
<PAGE>
Item 5. Other Events
On April 14, 1997, by unanimous written consent, the Directors of American
Pharmaceutical Company extended to expiration date of the Company's Class B and
Class C Warrants to October 31, 1997.
SIGNATURES
Pursuant to the requirements of the Securities and Exchange Act of 1934, the
Registrant has duly caused this report to be signed in its behalf by the
undersigned thereunto duly authorized.
AMERICAN PHARMACEUTICAL COMPANY
DATED April 14, 1997 By: /s/Christian M. Van Pelt
--------------------------------------------
Christian M. Van Pelt, Chairman of the Board
& Secretary
DATED April 14, 1997 By: /s/Alfred C. Bagwell
--------------------------------------------
Alfred C. Bagwell, President & CEO
